FLT3 and acute myeloid leukemia: Furthermore, in vitro analysis of FLT3 inhibitors with varying levels of selectivity suggests that less-selective FLT3 inhibitors or those with broader tyrosine kinase inhibition profiles may offer a cytotoxic advantage in patients with newly diagnosed AML [5].